Abciximab
The therapeutic efficacy of Abciximab can be decreased when used in combination with Medroxyprogesterone acetate.
Acarbose
The therapeutic efficacy of Acarbose can be decreased when used in combination with Medroxyprogesterone acetate.
Acenocoumarol
Medroxyprogesterone acetate may decrease the anticoagulant activities of Acenocoumarol.
Advertisement
Acetohexamide
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Medroxyprogesterone acetate.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
Acitretin
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Acitretin.
Advertisement
Adapalene
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Adapalene.
Alitretinoin
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Alitretinoin.
Alogliptin
The therapeutic efficacy of Alogliptin can be decreased when used in combination with Medroxyprogesterone acetate.
Advertisement
Amiodarone
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Amiodarone.
Amobarbital
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Amobarbital.
Amodiaquine
The serum concentration of Amodiaquine can be increased when it is combined with Medroxyprogesterone acetate.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Medroxyprogesterone acetate.
Ancrod
The therapeutic efficacy of Ancrod can be decreased when used in combination with Medroxyprogesterone acetate.
Antithrombin III
The therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Medroxyprogesterone acetate.
Antithrombin III, Human
The therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Medroxyprogesterone acetate.
Apalutamide
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Apalutamide.
Apixaban
The therapeutic efficacy of Apixaban can be decreased when used in combination with Medroxyprogesterone acetate.
Aprepitant
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Aprepitant.
Ardeparin
The therapeutic efficacy of Ardeparin can be decreased when used in combination with Medroxyprogesterone acetate.
Argatroban
The therapeutic efficacy of Argatroban can be decreased when used in combination with Medroxyprogesterone acetate.
Argatroban Anhydrous
The therapeutic efficacy of Argatroban can be decreased when used in combination with Medroxyprogesterone acetate.
Aripiprazole
The serum concentration of Aripiprazole can be decreased when it is combined with Medroxyprogesterone acetate.
Artemether
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Artemether.
Atazanavir
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Atazanavir.
Atomoxetine
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Atomoxetine.
Barbexaclone
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Barbexaclone.
Barbital
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Barbital.
Becaplermin
The therapeutic efficacy of Becaplermin can be decreased when used in combination with Medroxyprogesterone acetate.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Medroxyprogesterone acetate.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Medroxyprogesterone acetate.
Bexarotene
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Bexarotene.
Bivalirudin
The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medroxyprogesterone acetate.
Boceprevir
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Boceprevir.
Bortezomib
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Bosentan.
C1 esterase inhibitor (human)
Medroxyprogesterone acetate may increase the thrombogenic activities of Human C1-esterase inhibitor.
C1 esterase inhibitor (recombinant)
Medroxyprogesterone acetate may increase the thrombogenic activities of Conestat alfa.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Medroxyprogesterone acetate.
Canagliflozin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.
Canagliflozin Anhydrous
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.
Carbamazepine
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Carbamazepine.
Ceritinib
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ceritinib.
Certoparin
The therapeutic efficacy of Certoparin can be decreased when used in combination with Medroxyprogesterone acetate.
Chlorpropamide
The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Medroxyprogesterone acetate.
Cholestyramine Resin
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Cholestyramine.
Citric Acid
The therapeutic efficacy of Citric Acid can be decreased when used in combination with Medroxyprogesterone acetate.
Citric Acid, Anhydrous
The therapeutic efficacy of Citric Acid can be decreased when used in combination with Medroxyprogesterone acetate.
Clarithromycin
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Clarithromycin.
Clemastine
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Clemastine.
Clobazam
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Clobazam.
Clotrimazole
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Clotrimazole.
Cobicistat
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Cobicistat.
Colesevelam
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Colesevelam.
Colestipol
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Colestipol.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Medroxyprogesterone acetate.
Crizotinib
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Crizotinib.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Medroxyprogesterone acetate.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Medroxyprogesterone acetate.
Cyclosporine
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Cyclosporine.
Dabigatran Etexilate
The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medroxyprogesterone acetate.
Dabrafenib
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Dabrafenib.
Dalteparin
The therapeutic efficacy of Dalteparin can be decreased when used in combination with Medroxyprogesterone acetate.
Danaparoid
The therapeutic efficacy of Danaparoid can be decreased when used in combination with Medroxyprogesterone acetate.
Darunavir
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Darunavir.
Dasatinib
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Deferasirox.
Delavirdine
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Delavirdine.
Desirudin
The therapeutic efficacy of Desirudin can be decreased when used in combination with Medroxyprogesterone acetate.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
Dextran
The therapeutic efficacy of Dextran can be decreased when used in combination with Medroxyprogesterone acetate.
Dextran 40
The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Medroxyprogesterone acetate.
Dextran 70
The therapeutic efficacy of Dextran 70 can be decreased when used in combination with Medroxyprogesterone acetate.
Dextran 75
The therapeutic efficacy of Dextran 75 can be decreased when used in combination with Medroxyprogesterone acetate.
Dicumarol
Medroxyprogesterone acetate may decrease the anticoagulant activities of Dicoumarol.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
Digoxin
Digoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
Dihydroergotamine
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Dihydroergotamine.
Diltiazem
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Diltiazem.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Medroxyprogesterone acetate.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Medroxyprogesterone acetate.
Doxycycline
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Doxycycline.
Dronedarone
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Dronedarone.
Dulaglutide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Medroxyprogesterone acetate.
Edetic Acid
The therapeutic efficacy of Edetic Acid can be decreased when used in combination with Medroxyprogesterone acetate.
Edoxaban
The therapeutic efficacy of Edoxaban can be decreased when used in combination with Medroxyprogesterone acetate.
Efavirenz
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Efavirenz.
Empagliflozin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.
Enoxaparin
The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medroxyprogesterone acetate.
Enoxaparin sodium
The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medroxyprogesterone acetate.
Enzalutamide
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Enzalutamide.
Erythromycin
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Erythromycin.
Eslicarbazepine Acetate
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Eslicarbazepine acetate.
Ethylenediaminetetraacetate
The therapeutic efficacy of Edetic Acid can be decreased when used in combination with Medroxyprogesterone acetate.
Exenatide
The therapeutic efficacy of Exenatide can be decreased when used in combination with Medroxyprogesterone acetate.
Felbamate
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Felbamate.
Ferulic Acid
The therapeutic efficacy of Ferulic acid can be decreased when used in combination with Medroxyprogesterone acetate.
Flibanserin
The serum concentration of Flibanserin can be increased when it is combined with Medroxyprogesterone acetate.
Fluconazole
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Fluconazole.
Fluindione
Medroxyprogesterone acetate may decrease the anticoagulant activities of Fluindione.
Fluvoxamine
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Fluvoxamine.
Fondaparinux
The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Medroxyprogesterone acetate.
Fondaparinux sodium
The therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Medroxyprogesterone acetate.
Fosamprenavir
The serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Medroxyprogesterone acetate resulting in a loss in efficacy.
Fosaprepitant
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Fosaprepitant.
Fosphenytoin
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Fosphenytoin.
Fusidate
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Fusidic Acid.
Glibornuride
The therapeutic efficacy of Glibornuride can be decreased when used in combination with Medroxyprogesterone acetate.
Gliclazide
The therapeutic efficacy of Gliclazide can be decreased when used in combination with Medroxyprogesterone acetate.
Glimepiride
The therapeutic efficacy of Glimepiride can be decreased when used in combination with Medroxyprogesterone acetate.
Glipizide
The therapeutic efficacy of Glipizide can be decreased when used in combination with Medroxyprogesterone acetate.
Gliquidone
The therapeutic efficacy of Gliquidone can be decreased when used in combination with Medroxyprogesterone acetate.
Glyburide
The therapeutic efficacy of Glyburide can be decreased when used in combination with Medroxyprogesterone acetate.
Griseofulvin
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Griseofulvin.
Griseofulvin microsize
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Griseofulvin.
Heparin
The therapeutic efficacy of Heparin can be decreased when used in combination with Medroxyprogesterone acetate.
Hexobarbital
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Hexobarbital.
Hypoxis hemerocallidea root extract
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with St. John's Wort.
Idelalisib
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Idelalisib.
Imatinib
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Imatinib.
Indinavir
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Indinavir.
Insulin Detemir
The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin Glargine
The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Medroxyprogesterone acetate.
insulin human, rDNA origin
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin Lispro
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin, Aspart Protamine, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin, Aspart, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin, Glulisine, Human
The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin, Protamine Lispro, Human
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin, Regular, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Medroxyprogesterone acetate.
Isavuconazole
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Isavuconazonium.
Isotretinoin
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Isotretinoin.
Isradipine
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Isradipine.
Itraconazole
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Itraconazole.
Ivacaftor
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ivacaftor.
Ketoconazole
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ketoconazole.
Lamotrigine
Medroxyprogesterone acetate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.
Lepirudin
The therapeutic efficacy of Lepirudin can be decreased when used in combination with Medroxyprogesterone acetate.
Linagliptin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Medroxyprogesterone acetate.
Liraglutide
The therapeutic efficacy of Liraglutide can be decreased when used in combination with Medroxyprogesterone acetate.
Lopinavir
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Lopinavir.
Lovastatin
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Lovastatin.
Luliconazole
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Lumacaftor.
Mephobarbital
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Methylphenobarbital.
Metformin
The therapeutic efficacy of Metformin can be decreased when used in combination with Medroxyprogesterone acetate.
Methohexital
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Methohexital.
Metreleptin
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Metreleptin.
Mifepristone
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Mifepristone.
Miglitol
The therapeutic efficacy of Miglitol can be decreased when used in combination with Medroxyprogesterone acetate.
Miglustat
The therapeutic efficacy of Miglustat can be decreased when used in combination with Medroxyprogesterone acetate.
Mitotane
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mitotane.
MYCOPHENOLATE
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mycophenolic acid.
Mycophenolic Acid
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mycophenolic acid.
Nadroparin
The therapeutic efficacy of Nadroparin can be decreased when used in combination with Medroxyprogesterone acetate.
Nateglinide
The therapeutic efficacy of Nateglinide can be decreased when used in combination with Medroxyprogesterone acetate.
Nefazodone
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Nefazodone.
Nelfinavir
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Nelfinavir.
Netupitant
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Netupitant.
Nevirapine
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Nevirapine.
Nilotinib
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Nilotinib.
Olaparib
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Olaparib.
Osimertinib
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Osimertinib.
Ouabain
Ouabain may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
Oxcarbazepine
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Oxcarbazepine.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Medroxyprogesterone acetate.
Palbociclib
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Palbociclib.
Pentaerythritol Tetranitrate
The therapeutic efficacy of Pentaerythritol Tetranitrate can be decreased when used in combination with Medroxyprogesterone acetate.
Pentobarbital
The metabolism of Medroxyprogesterone acetate can be increased when combined with Pentobarbital.
Pentosan Polysulfate
The therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Medroxyprogesterone acetate.
Perampanel
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Perampanel.
Phenformin
The therapeutic efficacy of Phenformin can be decreased when used in combination with Medroxyprogesterone acetate.
Phenindione
Medroxyprogesterone acetate may decrease the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Medroxyprogesterone acetate can be increased when combined with Phenobarbital.
Phenprocoumon
Medroxyprogesterone acetate may decrease the anticoagulant activities of Phenprocoumon.
Phenytoin
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Phenytoin.
Pioglitazone
The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Medroxyprogesterone acetate.
Posaconazole
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Posaconazole.
Pramlintide
The therapeutic efficacy of Pramlintide can be decreased when used in combination with Medroxyprogesterone acetate.
Primidone
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Primidone.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
protein C, human
The therapeutic efficacy of Protein C can be decreased when used in combination with Medroxyprogesterone acetate.
protein S, human
The therapeutic efficacy of Protein S human can be decreased when used in combination with Medroxyprogesterone acetate.
Protocatechualdehyde
The therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Medroxyprogesterone acetate.
Ranolazine
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Ranolazine.
Regular Insulin, Human
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Medroxyprogesterone acetate.
Repaglinide
The therapeutic efficacy of Repaglinide can be decreased when used in combination with Medroxyprogesterone acetate.
Reviparin
The therapeutic efficacy of Reviparin can be decreased when used in combination with Medroxyprogesterone acetate.
Reviparin sodium
The therapeutic efficacy of Reviparin can be decreased when used in combination with Medroxyprogesterone acetate.
Rifabutin
The metabolism of Medroxyprogesterone acetate can be increased when combined with Rifabutin.
Rifampin
The metabolism of Medroxyprogesterone acetate can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Medroxyprogesterone acetate can be increased when combined with Rifapentine.
Rifaximin
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Rifaximin.
Rilpivirine
The serum concentration of Rilpivirine can be decreased when it is combined with Medroxyprogesterone acetate.
Rivaroxaban
The therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Medroxyprogesterone acetate.
Rosiglitazone
The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Medroxyprogesterone acetate.
Rucaparib
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Rucaparib.
Saquinavir
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Saquinavir.
Saquinavir Mesylate
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Sarilumab.
Saxagliptin
The serum concentration of Saxagliptin can be decreased when it is combined with Medroxyprogesterone acetate.
Saxagliptin Anhydrous
The serum concentration of Saxagliptin can be decreased when it is combined with Medroxyprogesterone acetate.
Secobarbital
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Secobarbital.
Selegiline
The serum concentration of Selegiline can be increased when it is combined with Medroxyprogesterone acetate.
Sildenafil
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Simeprevir.
Sitagliptin
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Medroxyprogesterone acetate.
Sitagliptin Phosphate
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Medroxyprogesterone acetate.
ST. JOHN'S WORT EXTRACT
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with St. John's Wort.
Sugammadex
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Sugammadex.
Sulfisoxazole
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Sulfisoxazole.
Telaprevir
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Telaprevir.
Telithromycin
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Telithromycin.
Thalidomide
Medroxyprogesterone acetate may increase the thrombogenic activities of Thalidomide.
Thiamylal
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Thiamylal.
Thiopental
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Thiopental.
Thiopental Sodium
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Thiopental.
Ticlopidine
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Ticlopidine.
Tipiracil
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Tipiracil.
Tipranavir
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Tipranavir.
Tocilizumab
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Tocilizumab.
Tolazamide
The therapeutic efficacy of Tolazamide can be decreased when used in combination with Medroxyprogesterone acetate.
Tolbutamide
The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Medroxyprogesterone acetate.
Topiramate
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Topiramate.
Tranexamic Acid
Tranexamic Acid may increase the thrombogenic activities of Medroxyprogesterone acetate.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Medroxyprogesterone acetate.
Tretinoin
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Tretinoin.
Troglitazone
The therapeutic efficacy of Troglitazone can be decreased when used in combination with Medroxyprogesterone acetate.
Troxerutin
The therapeutic efficacy of Troxerutin can be decreased when used in combination with Medroxyprogesterone acetate.
Ulipristal
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Ulipristal.
Vemurafenib
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Verapamil.
Vildagliptin
The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Medroxyprogesterone acetate.
Voriconazole
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Voriconazole.
Warfarin
Medroxyprogesterone acetate may decrease the anticoagulant activities of Warfarin.
Ziprasidone
The metabolism of Medroxyprogesterone acetate can be decreased when combined with Ziprasidone.
